Why consider treatment in China for Multiple Myeloma?

China offers cutting-edge therapies at a fraction of Western costs, including VRd induction, autologous stem cell transplantation (HSCT), and domestically developed BCMA CAR-T therapies like cilta-cel and equecabtagene autoleucel. Many Chinese oncology centers have high patient volumes and deep expertise in managing relapsed/refractory disease. The combination of advanced technology, experienced specialists, and significantly lower prices makes China a compelling option for international patients.